Skip to main content

Life Sciences is now live. See how →

Patent Examiner Joseph G. Dauner

Art Unit 1682 · Nucleic Acid Assays & Disease Biomarkers · Tech Center 1600 · 217 applications filed 2021–2026

⚑ Hard · harder than 72% of examiners● Free examiner data

Joseph G. Dauner is a USPTO patent examiner in Art Unit 1682 (Nucleic Acid Assays & Disease Biomarkers) with 217 applications from filing years 2021–2026. Examiner Dauner's allowance rate is 71.3%, below the 82.5% USPTO average for applications filed in the same years. The examiner ranks harder than 72% of examiners. In 2021, decided applications with an examiner interview were allowed 14.5 percentage points more often than those without.

Draft a response to Examiner DaunerSee the strategy data ↓

Data through October 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Hard
harder than 72% of examiners
Easier72nd percentileHarder
Allowance rate vs peers
Examiner Dauner71.3%
Art Units 1634 and 168249.4%
USPTO average82.5%
Allowance rate
71.3%
▼ USPTO avg 82.5%
Applications
217
filing years 2021–2026
First-action allowance
3.7%
patented with no rejection
Abandoned
14.3%
share of applications
Avg office actions
1.6
USPTO avg 1.3
Days to first OA
784
▲ USPTO 622
RCE rate
23.0%
USPTO 19.4%
Interview rate
25.8%
USPTO 27.3%

Examiner details

  • Art unit1682 · Nucleic Acid Assays & Disease Biomarkers
  • Title / gradePrimary Patent Examiner · GS-14
  • Service16 years
  • PhoneOn each office action
  • Email[email protected]
  • In USPTO recordsDAUNER, JOSEPH G
Full signatory authority

Examiner Dauner can allow an application without a supervisory sign-off.

Examines (USPC classes)
435 · Chemistry: Molecular Biology & Microbiology506 · Combinatorial Chemistry Technology (Method, Library, Apparatus)

How to improve your odds with Examiner Dauner

  • The data favors an interview. Interviewed cases were allowed more often in all 3 measured years, by 14.5 to 31.7 points.
  • Plan for the timeline. First office action averages 784 days vs the 622-day USPTO norm.
  • Expect a §112. Definiteness & disclosure is the most-issued rejection (152), and applicants overcame it 60.6% of the time.
  • The data cuts against an RCE. Cases with an RCE were allowed less often in both measured years, by 5.7 to 22.2 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§101 Eligibility49 issued · 51.7% overcome
§102 Novelty103 issued · 65.2% overcome
§103 Obviousness136 issued · 51.7% overcome
§112 Definiteness & disclosure152 issued · 60.6% overcome
How applicants traverse §112 rejections🔒 Members

Applicants overcame 60 of the 99 decided §112 definiteness & disclosure rejections from Examiner Dauner in the data. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §112 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Dauner?

Draft your response with Examiner Dauner's record and Art Unit 1682's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response tools in AI Studio.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Dauner.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202232.8%62.5%68.2%-5.7pp
202128.8%55.6%77.8%-22.2pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/629059Fluidics Systems for Sequential Delivery of ReagentsAbandoned3🔒 View
17/942887Array-Based Methods for Analysing Mixed Samples Using Differently Labelled Allele-Specific ProbesAbandoned2🔒 View
18/589016Nucleic Acid Control Molecules from Non-Human OrganismsPatented1🔒 View
17/917902EPLIN as a Biomarker for CancerPatented2🔒 View
See all 217 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1682 technology

Nucleic acid diagnosticsCancer biomarkersAmplification & sequencingPathogen detectionTop CPC C12Q · A61K · C12N
About this examiner. Joseph G. Dauner examines in Art Unit 1682 (Nucleic Acid Assays & Disease Biomarkers, Tech Center 1600). The art unit's docket includes nucleic acid diagnostics, cancer biomarkers, amplification & sequencing, and pathogen detection. Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Joseph G. Dauner's allowance rate?
Examiner Dauner's allowance rate is 71.3%, compared with 82.5% across the USPTO and 49.4% in Art Units 1634 and 1682 for applications filed in the same years. That rate ranks Examiner Dauner harder than 72% of examiners.
Is Examiner Dauner a hard examiner?
Somewhat. Examiner Dauner ranks harder than 72% of examiners, in the 72nd difficulty percentile (hard). Examiner Dauner has a 71.3% allowance rate versus 82.5% across the USPTO and 49.4% in Art Units 1634 and 1682, 1.6 office actions per application versus 1.3, and an RCE rate of 23.0% versus 19.4% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Dauner?
In this examiner's record, yes. Decided applications with an interview were allowed more often in each of the 3 measured years, by 14.5 to 31.7 percentage points. In 2021, 82.4% of decided applications with an interview were allowed, versus 67.9% of those without.
What is Examiner Dauner's most common rejection?
§112 definiteness & disclosure, issued 152 times in the data. Applicants overcame it 60.6% of the time.
Is an RCE worth filing with Examiner Dauner?
Not in this examiner's record. Decided applications with an RCE were allowed less often in both measured years, by 5.7 to 22.2 percentage points. In 2021, 55.6% of decided applications with an RCE were allowed, versus 77.8% of those without one.
How long until the first office action from Examiner Dauner?
About 784 days on average, versus 622 days across the USPTO for applications filed in the same years.
How do I contact Examiner Joseph G. Dauner?
Examiner Dauner can be reached by email at [email protected]. The examiner's direct line is listed at the end of the examiner's office actions.

Put Examiner Dauner's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Joseph G. Dauner, or see an error? Request a correction.